60 completed, 11 withdrawn, 9 terminated, 8 unknown. 38 Phase 2, 17 Phase 3, 15 Phase 4, 14 Not applicable, 8 Early Phase 1.
Follow D-cycloserine: new trials by email Literature Review of D-cycloserine trials Research Report on D-cycloserine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder Sham iTBS, TMS, D-cycloserine - Major Depression, Healthy Participants | Phase 1 / Phase 2 | Not yet recruiting | Mclean Hospital | 100 | 2026-09-01 | 2026-08-14 |
| Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study) Varenicline, Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham - Nicotine Dependence, Transcranial Magnetic Stimulation | Phase 4 | Recruiting | Massachusetts General Hospital | 30 | 2026-07-02 | 2026-09-15 |
| D-Cycloserine for Serine Palmitoyltransferase Inhibition D-cycloserine - Hereditary Spastic Paraplegia | Phase 4 | Completed | Massachusetts General Hospital | 1 | 2024-07-10 | 2026-04-21 |
| iTBS+D-Cycloserine for Youth Suicide D-Cycloserine, intermittent Theta-Burst-repetitive Transcranial Magnetic Stimulation, Placebo oral tablet - Suicidal Ideation, Suicide, Attempted | Phase 2 | Recruiting | University of Calgary | 54 | 2024-03-11 | 2024-11-12 |
| Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine d-cycloserine, Juul e-cigarette - Smoking Cessation, Harm Reduction | Phase 2 | Completed | Rose Research Center, LLC | 25 | 2023-10-20 | 2026-01-20 |
| D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT) D-Cycloserine, Intermittent Theta Burst Stimulation - Major Depressive Disorder | Phase 2 | Active not recruiting | The Alfred | 180 | 2023-04-21 | 2025-12-04 |
| D-cycloserine Augmented Treatment for Youth With Tic Disorders d-cycloserine, Placebo pill, Behavior Therapy - Tourette Syndrome | Early Phase 1 | Withdrawn | Johns Hopkins University | 2023-04-15 | 2023-04-14 | |
| D-Cycloserine+iTBS PK Study D-cycloserine, Transcranial Magnetic Stimulator - Major Depressive Disorder | Phase 1 | Completed | University of Calgary | 12 | 2022-10-12 | 2023-09-11 |
| iTBS-DCS in Fibromyalgia D-Cycloserine, Placebo oral tablet, iTBS repetitive Transcranial Magnetic Stimulation (rTMS) - Fibromyalgia | Phase 2 | Terminated | University of Calgary | 47 | 2022-08-29 | 2025-08-17 |
| iTBS-DCS in Obsessive Compulsive Disorder iTBS repetitive Transcranial Magnetic Stimulation (rTMS), Sham rTMS, D-cycloserine - Obsessive-Compulsive Disorder | Phase 2 | Unknown | University of Calgary | 81 | 2021-11-26 | 2023-09-13 |
| Pain, Learning, and Nocebo D-cycloserine, Conditioning, Extinction - Chronic Pain, Pain Syndrome | Not applicable | Completed | Leiden University Medical Center | 53 | 2021-02-28 | 2022-01-11 |
| Multimodal Cue Exposure Therapy for Smoking Cessation D-Cycloserine, Placebo oral tablet, Open Phase CBT that preceeds the randomization phase - Smoking Cessation | Phase 2 | Withdrawn | Boston University Charles River Campus | 2020-10-01 | 2021-02-12 | |
| AIH for Spinal Cord Repair hypoxia, sham hypoxia, D-cycloserine - SCI | Early Phase 1 | Terminated | VA Office of Research and Development | 50 | 2020-02-25 | 2026-02-27 |
| Adjunctive D-Cycloserine in Major Depressive Disorder D-cycloserine, Transcranial Magnetic Stimulator, Placebo oral capsule - Major Depressive Disorder | Phase 2 | Completed | University of Calgary | 50 | 2019-12-01 | 2022-01-10 |
| Lower Limb Function After Spinal Cord Injury D-Cycloserine, Placebo, Training - Spinal Cord Injury | Phase 4 | Completed | Shirley Ryan AbilityLab | 257 | 2019-06-21 | 2021-07-01 |
| The Effect of D-cycloserine on Emotional Processing d-cycloserine, Placebo - Cycloserine, Healthy Volunteer | Not applicable | Completed | University of Oxford | 40 | 2018-08-10 | 2019-05-23 |
| D-cycloserine for the Treatment of Chronic, Refractory Low Back Pain D-cycloserine, Placebo - Low Back Pain, Pain | Phase 2 | Terminated | Northwestern University | 203 | 2018-03-30 | 2026-05-04 |
| Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression Placebo, Fludrocortisone, D-Cycloserine - Major Depression | Not applicable | Completed | Charite University, Berlin, Germany | 232 | 2016-09-27 | 2020-06-23 |
| Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD CBT + ImRs, CBT + I.E., D-Cycloserine - PTSD | Phase 2 / Phase 3 | Withdrawn | Boston University Charles River Campus | 2016-09-01 | 2023-02-08 | |
| D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Ketamine, D-cycloserine, Placebo - Treatment Resistant Depression | Phase 4 | Unknown | Sheba Medical Center | 60 | 2016-06-01 | 2016-05-13 |
Showing 20 of 92. Sign in to see all of them.
Obsessive-Compulsive Disorder (11) · Stress Disorders, Post-Traumatic (11) · Schizophrenia (10) · Depressive Disorder, Major (8) · Anxiety Disorders (6) · Panic Disorder (5) · Phobia, Social (5) · Psychotic Disorders (5) · Pain (4) · Smoking Cessation (4) · Autistic Disorder (3) · Bipolar Disorder (3) · Chronic Pain (3) · Cognitive Dysfunction (3) · Depression (3)
Massachusetts General Hospital (14) · Boston University Charles River Campus (8) · University of Calgary (5) · University of California, Los Angeles (4) · Hartford Hospital (3) · Indiana University (3) · New York State Psychiatric Institute (3) · Northwestern University (3) · University of Oxford (3) · Charite University, Berlin, Germany (2) · Emory University (2) · Johns Hopkins University (2) · Mclean Hospital (2) · Tulane University School of Medicine (2) · University of South Florida (2)
United States (65) · Canada (6) · Israel (4) · Germany (3) · United Kingdom (3) · Australia (2) · Belgium (1) · Netherlands (1) · Norway (1) · Sweden (1)
Alexander McGirr, MD PhD (3) · Eric Storch, Ph.D. (3) · Alexander McGirr, MD, PhD (2) · Christopher J. McDougle, MD (2) · David Tolin, PhD (2) · Donald C Goff, M.D. (2) · Donald Goff, MD (2) · Mark H Pollack, MD (2) · Michael S Scheeringa, MD, MPH (2) · Michael W. Otto, Ph.D. (2) · Sabine Wilhelm, PhD (2) · A. Eden Evins, MD, MPH (1) · Aimee L McRae, Pharm.D. (1) · Andrea Reinecke, PhD (1) · Andrea WM Evers, PhD (1)
PMID 37811711, PMID 24506079, PMID 28569390, PMID 33583058, PMID 15474895, PMID 15502972, PMID 17898352, PMID 18799288, PMID 19811776, PMID 20817153, PMID 21292243, PMID 21723096, PMID 22694905, PMID 23059145, PMID 23098672, PMID 23332511, PMID 23599046, PMID 23870811, PMID 24038728, PMID 24485587, PMID 24743802, PMID 25441015, PMID 25970252, PMID 26111923, PMID 26587287, PMID 26770664, PMID 27183343, PMID 27315514, PMID 27367832, PMID 27852965, PMID 28138381, PMID 30059794, PMID 30149332, PMID 30877851, PMID 31279534, PMID 31368770, PMID 31622374, PMID 31908107, PMID 32004998, PMID 32229324, PMID 32496566, PMID 32722659, PMID 32789516, PMID 34010494, PMID 34134828, PMID 34510411, PMID 35141873, PMID 35612403, PMID 36223114, PMID 36572534
P50MH060450 (3), R01MH075889 (2), 1RC1MH088969-01 (1), 2014 (1), K23MH068627 (1), R01DA017904 (1), R01DK100924 (1), R01MH059807 (1), R01MH070880 (1), R01MH072961 (1), R01MH078308 (1), R01MH081116 (1), R01MH093402 (1), R21DA023588 (1), T32GM007748 (1)